|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GlaxoSmithKline
(RECEIVED May 21, 2008; ACCEPTED July 22, 2008)
VX-680, also known as MK-0457, is an ATP-competitive small molecule inhibitor of the Aurora kinases that has entered phase II clinical trials for the treatment of cancer. We have solved the co-crystal structure of AurA/TPX2/VX-680 at 2.3 Å resolution. In the crystal structure, VX-680 binds to the active conformation of Aur A. The glycine-rich loop in AurA adopts a unique bent conformation, forming a
-
interaction with the phenyl group of VX-680. In contrast, in the published AurA/VX-680 structure, VX-680 binds to AurA in the inactive conformation, interacting with a hydrophobic pocket only present in the inactive conformation. These data suggest that TPX2, a protein cofactor, can alter the binding mode of VX-680 with AurA. More generally, the presence of physiologically-relevant cofactor proteins can alter the kinetics, binding interactions, and inhibition of enzymes, and studies with these multi-protein complexes may be beneficial to discovery and optimization of enzyme inhibitors as therapeutic agents.
Keywords: Conformational changes; Enzymes; Active sites; Structure; Crystallography; Protein crystallization; Enzyme Inhibitors
1 E-mail: zhihong.v.lai{at}gsk.com
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |